Brilinta vs Crestor
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| US Brilinta | US Crestor | |
|---|---|---|
| Generic name | ticagrelor | rosuvastatin |
| Drug class | P2Y12 Platelet Inhibitor (Antiplatelet) | Statin |
| Treats | Acute coronary syndrome, heart attack prevention | High cholesterol, cardiovascular prevention |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | AstraZeneca | AstraZeneca |
| Year approved | 2011 | 2003 |
| FDA warning | Black box warning | No boxed warning |
| Est. TV ad spend | $120M | $45M |
| Common side effects | Bleeding, Shortness of breath, Bruising, Headache | Muscle pain, Headache, Liver problems, Increased blood sugar |
Frequently asked questions
Is Brilinta or Crestor better?
Neither is universally "better." Brilinta (ticagrelor) and Crestor (rosuvastatin) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Brilinta and Crestor?
Brilinta is a P2Y12 Platelet Inhibitor (Antiplatelet) made by AstraZeneca, while Crestor is a Statin made by AstraZeneca. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Brilinta has the larger estimated TV advertising budget of the two.